A vaccine primarily used for treating tuberculosis (TB) may be effective in reducing high blood sugar among people with Type - 1 diabetes results from a clinical trial has revealed. The findings showed that three years after receiving two administrations of the Bacillus Calmette-Guerin (BCG) vaccine four weeks apart people with longstanding Type-1 diabetes showed an improvement in HbA1c -- Aglycated haemoglobin -- measured to test the overall sugar levels to near normal levels. This is clinical validation of the potential to stably lower blood sugars to near normal levels with a safe vaccine even in patients with longstanding disease
